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REPLY
The comment by Harper and Haqqani, namely that a patent
foramen ovale (PFO) is unlikely to confer a significant mortality
disadvantage, indirectly acknowledges that it might. Paradoxical
embolism through a PFO can unequivocally have devastating
consequences, including death. Hence, even if no significant risk
for mortality has yet been proven, people die from it (1). This must
suffice to take the matter seriously. If there was a simple vaccina-
tion to close the PFO, it would be a world standard. Implantation
of a device in the heart, with an inherent risk for mortality as well,
needs proof of superiority over the natural course. This proof (or
disproof) is subject to time. About 1,000 patients have been
randomized between device closure and natural course in a variety
of trials in progress. Device implantation should show any disad-
vantage quite early as its risks are front-loaded. An advantage,
however, takes many years to unveil because events from a PFO are
fortunately rare (rarer than we initially thought), but not absent.
None of the trials has been stopped prematurely, which speaks
against a disadvantage without compromising the hope for an
advantage of PFO closure.
The theory of selective mortality of the PFO is indeed not in
keeping with the finding that the fewer PFOs in the elderly are
larger in size (2). The theory of late spontaneous fusion by
increasing left atrial pressure with age could explain that. Con-
versely, there is hard evidence for the first theory (people do die
from PFOs) but not for the second. The fact that patients with
mitral stenosis had a passable PFO in 1% according to Harper
and Haqqani is not sufficiently explained by either theory. The
bulging of the atrial septum into the right atrium in mitral stenosis
is likely to render catheter passage from the inferior vena cava more
difficult as the PFO is hidden behind this bulge in a region where
the septum now is tangential to the catheter path, making probing
for the PFO unyielding. Many PFOs go undetected under these
circumstances, although they are not fused but simply functionally
closed by elevated left atrial pressure and moved out of target for
access from the inferior vena cava.
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REPLY
We appreciate and acknowledge the interest in our recently reported
study (1). In regard to the comments of Schrale et al., we studied
subjects in age increments or “cells” of 10 years beginning at age 45,
and we did not find an increased stroke risk in even the younger age
cells. A recent case control study published by Petty et al. (2) supports
our finding that patent foramen ovale (PFO) does not appear to be a
risk factor for cryptogenic stroke in the general population.
Also, Harper and Haqqani provide intriguing thoughts regard-
ing the issue of PFO detection rates in older individuals. It is
possible that a PFO may close in older subjects, but this postulate
is based on many assumptions, including that older people have
elevated left atrial pressures. This is an interesting concept that
merits systematic evaluation.
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Coronary Plaque Burden
and Cardiovascular Risk Factors:
Single-Point Versus Serial Assessment
In their interesting study, Nicholls et al. (1) recently assessed in a
large series of patients the relation between various cardiovascular
risk factors and the amount of coronary plaque burden with
(non-serial) volumetric intravascular ultrasound (IVUS). In this set
of high-quality data, male gender, diabetes mellitus, and a history
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